{
    "nctId": "NCT01779531",
    "briefTitle": "Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients",
    "officialTitle": "A Phase III\uff0cRandomized \uff0cMulti-center Clinical Trail to Compare the Outcomes of XT and XEC Adjuvant Chemotherapy Protocol in HER-negative Luminal B Breast Cancer Patients Who Reached Pathologic Response After XT Neoadjuvant Chemotherapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 640,
    "primaryOutcomeMeasure": "Disease free survival after adjuvant chemotherapy within five years",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Chinese population surgery patients with invasive breast cancer\uff1b\n* Stage II-III\uff1b\n* ER positive\uff1b\n* HER2 negative\uff1b\n* Ki67\u226514%\uff1b\n* Aged between 18 and 70 years old\uff1b\n* The maximum diameter of the primary tumor greater than 1cm\uff1b\n* ECOG score 0-1 points\uff1b -Have adequate baseline bone marrow and organ function reserve : absolute neutrophil count \u2265 1500/mm3, platelet count \u2265 8g/dl; the \u2265 100000/mm3 hemoglobin concentration and serum creatinine \u2264 1.5 times the upper limit of normal ; aspartate aminotransferase and alanine aminotransferase \u2264 2.5 times the upper limit of normal , bilirubin \u2264 1.5 times the upper limit of normal ; left ventricular ejection fraction ( LVEF ) \u2265 50%\n\nExclusion Criteria: - Non - Chinese population of patients\uff1b\n\n* Non- invasive cancer patients;\n* Inflammatory Breast Cancer patients;\n* Metastatic breast cancer patients;\n* HER2 positive patients;\n* Ki67\\<14% patients;\n* No adequateBaseline bone marrow or organ function reserve;\n* ECOG PS score \u2265 2 points;\n* Younger than 18 years of age or greater than 70 years old;\n* Already accepted therapy including chemotherapy , endocrine therapy or targeted therapy before neoadjuvant treatment;\n* HER2-positive patients with left ventricular ejection fraction less than 55 % can not receiving Herceptin;\n* Known allergy of docetaxel , capecitabine , epirubicin , ring phosphonamide .",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}